CP-91149 is a selective glycogen phosphorylase (GP) inhibitor with IC50 of 0.13 μM in the presence of glucose, 5- to 10-fold less potent in the absence of glucose.
C, experimental design illustrating the time points in which PYGL inhibitor CP-91149 (GPi) and 2DG were added to the groups depicted in D to J. D, representative images of cell invasion through the Boyden chamber from control, 2DG and recovery GBM1 treated with GPi or DMSO. E to G, comparison of the invasive capacity of EV or shG6PC in the presence or absence of GPi.
Doxifluridine is an oral prodrug that is converted to the cytotoxic agent 5-fluorouracil (5-FU).
Tipiracil is an inhibitor of thymidine phosphorylase, the enzyme that degrades trifluridine into trifluorothymidine. Its combination with trifluridine increases the bioavailability of trifluridine.